Replies to post #111492 on Biotech Values

[mcbio]

AMGN’s 30-minute webcast at the DB conference was entirely devoted to the recently reported Xgeva results in bone-met prevention in CRPC

Presumably this bodes well for EXEL and XL184 in terms of its potential future role in bone-met treatment.